Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...

The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate symptom ...

Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...

PORTSMOUTH, N.H., Jan. 17, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leader in diagnostic and therapeutic medical technologies, has reached a significant milestone with its ...

The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...

Urotronic's Drug Coated Balloon Provides Minimally-Invasive, Durable Alternative for Stricture Patients in Europe MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical ...

Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...

Add Yahoo as a preferred source to see more of our stories on Google. May 18—MORGANTOWN — Mon Health Medical Center achieved another first this month — becoming the first in the state to offer a novel ...

PORTSMOUTH, N.H., Oct. 28, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp (Laborie), announced today that the American Medical ...

Inflating a drug-coated balloon in the prostate is the latest approach to treating a common cause of frequent or difficult urination in older men. More recently, researchers have developed various ...